أعضاء هيئة التدريس - جامعة بنها
The Impact of Comorbidities on the Outcomes of Egyptian COVID-19 Patients: A Follow-Up Study
Journal of Environmental and Public Health • 2021
معلومات البحث
المؤلفون
Reda M. Albadawy, Bismeen A. Jadoon, Mysara M. Mogahed, Mohamed E. Ibrahim, Tarek S. Essawy, Ahmed M. A. Amin, Marwa S. Abd-Elraouf and Mona A. Elawady5
الكلمات المفتاحية
Not Available
المجلة العلمية
Journal of Environmental and Public Health
الناشر
Not Available
المجلد
Not Available
العدد
Not Available
الصفحات
Not Available
publication.type
International
رابط البحث
Not Available
المواد المرفقة
Not Available
الملخص
Objectives. +is study evaluated the clinical manifestation of COVID-19 and adverse outcomes in patients with comorbidities (outcome: death). Methods. A comparative follow-up investigation involving 148 confirmed cases of COVID-19 was performed for a month (between April and May 2020) at Qaha Hospital to describe the clinical characteristics and outcomes resulting from
comorbidities. Participants were divided into two clusters based on the presence of comorbidities. Group I comprised cases with comorbidities, and Group II included subjects without comorbidity. Survival distributions were outlined for the group with
comorbidities after the follow-up period. Results. Fever (74.3%), headache (78.4%), cough (78.4%), sore throat (78.4%), fatigue (78.4%), and shortness of breath (86.5%) were the most prevalent symptoms observed in COVID-19 patients with comorbidities.
Such patients also suffered from acute respiratory distress syndrome (37.8%) and pneumonia three times more than patients without comorbidities. +e survival distributions were statistically significant (chi-square � 26.06, p ≤ 0.001).
Conclusion. Multiple comorbidities in COVID-19 patients are linked to severe clinical symptoms, disease complications, and critical disease progression. +e presence of one or more comorbidities worsened the survival rate of patients.
comorbidities. Participants were divided into two clusters based on the presence of comorbidities. Group I comprised cases with comorbidities, and Group II included subjects without comorbidity. Survival distributions were outlined for the group with
comorbidities after the follow-up period. Results. Fever (74.3%), headache (78.4%), cough (78.4%), sore throat (78.4%), fatigue (78.4%), and shortness of breath (86.5%) were the most prevalent symptoms observed in COVID-19 patients with comorbidities.
Such patients also suffered from acute respiratory distress syndrome (37.8%) and pneumonia three times more than patients without comorbidities. +e survival distributions were statistically significant (chi-square � 26.06, p ≤ 0.001).
Conclusion. Multiple comorbidities in COVID-19 patients are linked to severe clinical symptoms, disease complications, and critical disease progression. +e presence of one or more comorbidities worsened the survival rate of patients.